Prestige Consumer Healthcare Finalizes LaCorium Acquisition, Prices $400M Senior Notes at 6.25%
PBH sits 16% above its 52-week low of $42.62.
Summary
Prestige Consumer Healthcare completed its $150 million LaCorium Health acquisition and finalized the pricing of a $400 million debt refinancing at a higher interest rate but longer maturity.
Key Events · Financing and Capital Events · PBH
-
LaCorium Health Acquisition Completed
Prestige Consumer Healthcare finalized the acquisition of LaCorium Health for approximately $150 million, expanding its therapeutic skin care portfolio.
-
New Term Loan for Acquisition
The company secured an additional $95 million term loan through an amendment to its existing credit agreement to partially finance the LaCorium Health acquisition.
-
Senior Notes Offering Priced
Prestige priced a private offering of $400 million in 6.25% senior notes due 2034.
-
Debt Refinancing Completed
Proceeds from the new notes will be used to redeem $400 million of existing 5.125% senior notes due 2028, extending debt maturity but at a higher interest cost.
Analysis · PBH · Life Sciences
This filing details the completion of the $150 million LaCorium Health acquisition, financed in part by a new $95 million term loan. Concurrently, the company priced a $400 million senior notes offering at 6.25% due 2034, which will refinance existing 5.125% notes due 2028. While the refinancing extends debt maturity, it comes at a higher interest rate, impacting future interest expenses. The acquisition is a strategic move to expand its therapeutic skin care portfolio.
At the time of this filing, PBH was trading at $49.42 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $42.62 to $80.69. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.